RecruitingPhase 3NCT02932618
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Studying Von Willebrand disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Baxalta now part of Shire
- Principal Investigator
- Study DirectorTakeda
- Intervention
- Vonicog alfa(biological)
- Enrollment
- 31 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2017 – 2026
Study locations (30)
- University of Colorado Hemophilia & Thrombosis Center, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida College of Medicine, Jacksonville, Florida, United States
- Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
- Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- St. Jude Affiliate Clinic at Novant Health, Charlotte, North Carolina, United States
- Comprehensive Cancer Center of Wake Forest Unversity, Winston-Salem, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Texas Children's Cancer and Hematology Center, Houston, Texas, United States
- Texas Children's Hospital, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Takeda Development Center Americas, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02932618 on ClinicalTrials.govOther trials for Von Willebrand disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07404644An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT07115004Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)Vega Therapeutics, Inc
- RECRUITINGPHASE3NCT07129343A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06998524A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseHoffmann-La Roche
- RECRUITINGNCT06883240An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentHoffmann-La Roche
- RECRUITINGPHASE3NCT05582993A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06205095A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWDUnity Health Toronto
- RECRUITINGPHASE1, PHASE2NCT05776069Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)Vega Therapeutics, Inc